<DOC>
	<DOC>NCT00447057</DOC>
	<brief_summary>This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival [PFS], disease control rate, best response rate, time to treatment failure [TTTF], overall survival [OS] and 1-year survival rates) compared to pemetrexed plus erlotinib combination.</brief_summary>
	<brief_title>Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is of nonsquamous histology and not amenable to curative therapy. Failure of previous treatment with one prior platinumbased chemotherapy regimen. Good performance status. Adequate bone marrow reserve, renal and hepatic functions. Serious concomitant systemic disease. Inability to take oral medication. Inability or unwillingness to take vitamin supplementation and corticosteroids. Pregnancy / Breastfeeding. Treatment with certain medicines that prevent blood from clotting.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>nonsquamous</keyword>
</DOC>